Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By white_Tiger (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Baseball, Oscar Gamble, and Why Not To Ignore Your Bench [GeoWire Weekly No. 129]

% of readers think this story is Fact. Add your two cents.


Welcome to The GeoWire , your source for a Peek into GeoInvesting’s Research Coverage, Microcap Stock Education, Case Studies, Featured Videos, and More. Please share this if you like today’s newsletter and comment with any feedback.


If you are new or this was shared with you, you can join our email list here.

The Ratio Man And Investing In Your Bench

If you are immediately wondering what baseball has to do with investing, don’t worry, I’ll get to my “growing as an investor” teachable moment in a second. First, let’s talk about sports as an analogy that bleeds into that moment.

Have you ever heard of Oscar Gamble?

In 2014, Bill James wrote an article covering his analysis of the best ever players coming off the bench in baseball. If you are not a sports fanatic, the bench consists of the players that back up the starting player lineup. 

Bill concluded that Oscar Gamble’s “coming off the bench’ performance”  in 1979 was the best of all time (as of 2014). Oscar was an outfielder and designated hitter while in the major leagues between 1969 and 1985, a span during which he played for seven different teams.

He earned the nickname “Ratio Man,” slamming 200 home runs in just over 4500 at bats. In 1977, with the White Sox, he hit 31 home runs or one per 13.2 at-bats! That is absolutely crazy! Imagine having that type of multibagger stock stock hit ratio over your lifetime.

Here is what Bill James said about the Ratio Man:

“According to this process, the greatest bench season ever was by Oscar Gamble in 1979.   I’m actually 100% happy with that answer; I don’t have any problem with it at all.   Playing for two teams, Gamble in 1979 hit .358 with 19 homers, 64 RBI in 270 at bats.    With a terrific strikeout to walk ratio as well (28 strikeouts, 50 walks), Gamble had on base and slugging percentages in Ted Williams/Barry Bonds/Babe Ruth territory, .456 and .609.  This wasn’t done in the steroid era or the 1890s, and it wasn’t done in Coors Field or the Baker Bowl, and he wasn’t “really” a regular who slipped under the radar, and he wasn’t a one-year fluke like Showboat Fisher in 1930 or Chris Duncan in 2006; it is absolutely legit on every front.”

Switching gears to football, If you play fantasy football, you are well aware of what the bench is and the tough decisions you need to make from week to week when setting your starting line-up.

Bench players

There is no worse feeling than losing a playoff spot resulting from your decision to leave an average player on the bench that outperformed your starters, like Tom Brady or Patrick Maholmes.  

But if you are in a legacy league that allows you to keep a certain number of players from year to year, that feeling will be dwarfed by the regret of not taking the chance to drop one of your legacy stars to make room for new players who could be the next great player that everyone else wished they had on their team. Even Tom Brady was a backup at one time, as were Ben Roesthisberger, Eli Manning, Drew Brees and Dak Prescott, who all showed greatness early in their careers and went on to shape the history of football in their own ways. Take a look back at the top 25 single-game backup performances in history, and you will see even more names you recognize.

NAME DATE TM YDS TD Rating
Norm Van Brocklin 9/28/1951 LA 554 5 128.3
Matt Schaub 11/18/2012 HOU 527 5 121.7
Warren Moon 12/16/1990 HOU 527 3 123.1
Joe Burrow 12/26/2021 CIN 525 4 143.2
Ben Roethlisberger 10/26/2014 PIT 522 6 150.6
Boomer Esiason 11/10/1996 ARI 522 3 77.1
Dan Marino 10/23/1988 MIA 521 3 68.8
Matthew Stafford 1/1/2012 DET 520 5 103.8
Jared Goff 9/29/2019 LAR 517 2 80.3
Tom Brady 9/12/2011 NE 517 4 121.6
Derek Carr 10/30/2016 OAK 513 4 117.4
Phil Simms 10/13/1985 NYG 513 1 82.3
Eli Manning 9/16/2012 NYG 510 3 89.5
Drew Brees 11/19/2006 NO 510 2 91
Vince Ferragamo 12/26/1982 RAM 509 3 106.2
Ben Roethlisberger 12/10/2017 PIT 506 2 99.7
Tony Romo 10/6/2013 DAL 506 5 140
Drew Brees 11/1/2015 NO 505 7 131.7
Y.A. Tittle 10/28/1962 NYG 505 7 151.4
Elvis Grbac 11/5/2000 KC 504 2 99.9
Matt Ryan 10/2/2016 ATL 503 4 142
Philip Rivers 10/18/2015 SD 503 2 99.7
Ben Roethlisberger 12/20/2009 PIT 503 3 121.9
Dak Prescott 10/4/2020 DAL 502 4 112.9
Jake Plummer 10/31/2004 DEN 499 4 88.4

None of us have a crystal ball of course, and it’s easy to overthink the myriad of scenarios that roster revisions can result in, like a situation in which you “outsmart” yourself and sit Maholmes because your average “Joe” bench quarterback had a “better” match up…so you start Joe and he performs…well, like the average player that he is.

Even more frustrating is when you lose because most of your bench outperforms your starters in a playoff game.

I think you know where I am going with this.

Your Portfolio’s Bench

If you are like me, when it comes to investing you might have your top 5 starters, and then a bunch of positions where the conviction may not be as high, and then your bench that you still want to watch. 

Unfortunately, we all probably also experienced our bench positions outperforming our large “starting five” lineup or where your smaller positions do not come close to offsetting  losses of your larger starting positions.

Position sizing is one of the hardest aspects of investing. Some of my biggest wins were once-average-conviction stocks that turned into big position stocks over time. Conversely, I’ve had some high conviction stocks where things went terribly wrong.

And even if you are right, you could be wrong on timing and have to weigh the opportunity cost of not switching out some of the stocks you own for other stocks in your pipeline. Was it really a win for me when I waited for Koru Medical Systems, Inc. (NASDAQ:KRMD) to move from 8 cents in early 2008 to $12.84 in 2020, especially when you consider the bulk of that move happened from January 2018.

KRMD was a tiny low conviction, a “let’s see what happens position” when I first bought it in 2007/08 under 10 cents, which I added to along the way over its 13 year 15,900% multibagger run. 

I am obviously ok with how it played out. However, I am not sure if I would have felt the same way had I made a high conviction bet right out of the gates, waiting 13 years for it to play out and not having funds to buy other stocks to produce short-term cash flow – a necessity as a full-time investor.

And this is what similarly makes investing hard, especially in the microcap spectrum, where undervalued stock prices can be uncorrelated to the market and their fundamentals for longer than you want to tolerate, or where business plans just don’t  keep their momentum, and your investment ends up being a waste of time.

BOPs

Geoinvesting’s BOP Model Portfolio #11 illustrates some of these points.

In January 2026, we launched our Buy On Pullback GeoInvesting Model portfolio (BOP) strategy. We normally add 4 to 7 “unjustly punished” stocks to the BOP that we believe should bounce back within days to about 9 months. At least that is what we aim for. The first step we take when creating a BOP is to identify candidates for potential inclusion in the portfolio.

We opened BOP 11 on September 25, 2023, adding the seventh and last stock from the bench on November 27.

So far, it’s been a great ride with the 3 top-performing stocks carrying current returns of 98.8%, 54.0% and 27.4%. 

However, we left 6 stocks on the bench that, at their highs, performed remarkably well – one at its peak return of 114.7% beat all 7 starters, and two of those on the bench bettered all but the top stock in the starting lineup. 

  • Csp Inc. (NASDAQ:CSPI) (114.7% peak return) – Third party Information Technology Solutions (recently launched a proprietary cyber security product)
  • Semler Scientific, Inc. (NASDAQ:SMLR) (95.9% peak return) – Medical Device to test for the risk pulmonary artery disease (PAD)

To be fair, one of the stocks we moved up from the bench to a starting position is up about 40%. However, it still hurts to see some of your bench outperform your real portfolio.

Luckily, BOP 11 is currently posting an average return of  28.77% (including open and closed positions), beating the bench by 17%, which stands at an 11.77% return, and 7.73% more than the S&P 500, which stands at a 21.14% gain since 9/25/2023.  So, overall, it looks like we made the right decisions. 

Don’t get lazy or complacent as an investor

There is an important take away from all this. Admittedly, because BOP 11 was performing nicely out of the gates, we didn’t pay close enough attention to the bench. However, we should’ve kept analyzing the bench on a more frequent basis. So, the real lesson here is when you’re making a research pipeline stock list, don’t ignore your bench. You put them there for a reason. Monitor the developments to see if things have changed for better or for worse. 

In the case of CSPI, we would’ve noticed some important information arbitrage developments the company was talking about in its earnings call transcripts regarding:

  • Some banter about Nvidia Corporation (NASDAQ:NVDA).
  • The CEO’s wishes to increase the company’s dividend.
  • A Form 4 showing the CEO bought stock around $30, pre 2 for 1 stock split (when the stock didn’t move in reaction to its earnings release)

This was all before the stock took off to 60 bucks, pre 2 for 1 stock split, within a 2-week period.

By the way, if you still haven’t seen how our 10 previous BOPs did along with their their start to finish timeframes, we’d like to remind you:

3-31-2024 Buy on Pullback BOP 1 to 11 Returns and Periods

The BOP is the perfect strategy for the misunderstood and underfollowed microcap space, and has been Geoinvesting’s most consistent top performing model portfolio. If you are interested in learning more about the strategy, please watch this webinar

If you are a premium subscriber and not currently logged in, you can log in here to view The Associated Premium content. Once Logged in, Just click on The link for The Latest Issue Listed At top of your Home Page. If you are not a premium subscriber, please JOIN HERE.

The post Baseball, Oscar Gamble, and Why Not To Ignore Your Bench [GeoWire Weekly No. 129] appeared first on GeoInvesting.


Source: https://geoinvesting.com/baseball-oscar-gamble-why-not-ignore-bench/


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.